8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) January 12, 2015

STELLAR BIOTECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

British Columbia, Canada	000-54598	N/A
(State or other jurisdiction	(Commission	(I.R.S. Employer
of incorporation)	File Number)	Identification No.)

332 E. Scott Street

Port Hueneme, California 93041

(Address of principal executive offices) (Zip Code)

(805) 488-2800

(Registrant’s telephone number, including area code)

Not applicable.

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01                      Regulation FD Disclosure.

Representatives of Stellar Biotechnologies, Inc. (the “Company”) will be conducting meetings with investors beginning January 12, 2015, and will also be presenting at the 7th Annual Biotech ShowcaseTM conference in San Francisco. A copy of the corporate presentation is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1,  is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.

Item 9.01                      Financial Statements and Exhibits.

Exhibit No.	Description
99.1	January 2015 Corporate Presentation.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Stellar Biotechnologies, Inc.
Date: January 12, 2015	By: /s/ Kathi Niffenegger
	Name: Kathi Niffenegger
	Title: Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	January 2015 Corporate Presentation.

EX-99.1

Corporate Presentation

OTCQB: SBOTF / TSX-V: KLH

www.StellarBiotech.com

www.KLHsite.org

Safe Harbor

This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  Forward-looking statements may be identified by the use of words such as "anticipate," “believe,” "plan," “estimate,” "expect," "intend," "may," "will," "would," "could," "should," “might,” “potential,” or "continue" and variations or similar expressions.  Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance.  There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements.  Such risks include, but may not be limited to:  general economic and business conditions; technology changes; competition; changes in strategy or development plans; governmental regulations and the ability or failure to comply with governmental regulations; the timing of anticipated results; and other factors referenced in Stellar’s filings with securities regulators.  For a discussion of further risks and uncertainties related to our business, please refer to our public company reports filed with the TSX Venture Exchange and the U.S. Securities and Exchange Commission.   All forward-looking statements are made as of the date hereof and are subject to change.  Except as required by law, we assume no obligation to update such statements.  This presentation does not constitute an offer or solicitation of an offer for sale of any securities in any jurisdiction, including the United States. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the information contained in this presentation.

Note: All financial and stock price information is presented in U.S. dollars.

Powering and Improving Immunotherapy(TM) Unique, World-Leading Technology Specializing in sustainable/scalable and fully traceable supply of Keyhole Limpet Hemocyanin (KLH), the widely-used immune-stimulating protein. Fastest-Growing Biopharma Sector Stellar KLH products & technology target immunotherapy and immunodiagnostics, biopharma’s fastest-growing sectors. Strong Growth Roadmap Multiple commercial and clinical pathways. New expansion in core business of sustainable KLH manufacturing and supply. Environmental Advantage Our ground-breaking work revolutionized KLH manufacturing Unprecedented standards, competitive edge.

1999 Founding Private, U.S.-based company (Calif.) Aquaculture facility $1M NIH grant funding

2004 KLH supply agreements for cancer vaccines $3M NCI grant funding for development of GMP-grade KLH

2005-2009 Patent for KLH protein extraction methods (U.S., Canada, Europe) GMP KLH Vaccine & supply partnerships

2010-2011 Stellar public on TSX Venture Exchange (TSX-V: KLH) $3.1M financing NSF Phase IIb grant funding Diagnostic co-development agreement

2012-2014 Stellar on U.S. OTCQB Marketplace (OTCQB: SBOTF) Amaran Biotechnology collaboration (potential KLH carrier for OBI-822 in breast cancer) Araclon supply agreement  (KLH for beta-amyloid for Alzheimer’s) Biovest supply agreement (KLH for BiovaxID® in N-H Lymphoma) Exclusive WW C. diff license Multiple industry firsts in aquaculture science Expanded IP (mfg. & adjuvant technologies,  immunotherapy) KLH Site™ Master File submission to U.S. FDA CBER $12M financing

What is Keyhole Limpet Hemocyanin (KLH)?

Important immune-stimulating protein.

Only source is scarce marine mollusk.

40+ years safe use in clinical immunology.

Vital in preclinical and clinical research.

Rapid growth in immunotherapy = High demand.

KLH: A Complex Molecule

A single KLH subunit can be an immunotherapy carrier

www.KLHsite.org

Megathura Crenulata – Giant Keyhole Limpet

The Power of KLH:  Versatile, Safe, Widely Used

KLH in Active Immunotherapies

Celldex, OBI Pharma, Neovacs, Araclon, Biovest, Affiris, Bayer, Axon, Scripps, NCI, NINDS, MabVax, Baylor, Abramson, Loyola, Rockefeller, MSKCC, Stanford

KLH is used as a carrier molecule (ingredient) in a new class of treatment called “active immunotherapy”

KLH in  TDAR Immunotoxicology

Amgen, Pfizer, Roche, Novartis, Biogen Idec, Bristol-Myers, J&J, NIAID, GSK, Novo Nordisk, Genentech

KLH is also used alone, as an injectable to measure patient immune response to new drugs.

KLH Growing Demand & Market Potential

KLH-Based Active Immunotherapy Trials*

Clinical Status	Indication	Company or Institute
EU MAA review	N-H Lymphoma	Biovest (BiovaxID®)
Phase III	Glioblastoma Breast Cancer	Celldex  (Rindopepimut) OBI Pharma  (OBI-822)
Phase II	Crohn’s Disease Lupus Rheumatoid Arthritis Alzheimer’s Multiple Myeloma Melanoma Lymphoma Melanoma Ovarian Cancer Sarcoma Ovarian Cancer Leukemia	Neovacs  (TNF Kinoid) Neovacs  (IFNa Kinoid) Neovacs  (TNF Kinoid) Affiris/GSK  (AD02) Abramson Center Baylor Research Clinica Navarra Dermatologische Klinik Loyola University MabVax MabVax / NCI NCI
Phase I	Alzheimer’s Alzheimer’s N-H Lymphoma Brain Tumor Glioblastoma Lung Cancer Neuroblastoma Sarcoma, Neuroblast	Araclon / Grifols Axon Neurosciences Bayer  (Autologous) Rockefeller Roswell Park Sloan-Kettering Sloan-Kettering NCI

Major Disease Categories

Cancer

Inflammatory Disease

Alzheimer’s

Immune Disorders

KLH Market Potential

$10M to $200Mper Indication

Major Biopharma Use

Celldex, Neovacs, Affiris, OBI, Bayer, Peptinov, Scripps, NCI, Genentech, MabVax, Chilka, Baylor, Biovest, Peptivir, Abramson, MSKCC, Stanford

Pfizer, Sanofi, Merck, J&J

Not a comprehensive list. Not limited to Stellar KLH™. Does not include KLH in immunodiagnostics.

Clinical trial costs are the responsibility of  the sponsor company or institute.

Sources:  Clinicaltrials.gov, corporate news and websites, Decision Resources, Research & Markets, BCC Research, KLH Site.

Stellar Biotech: A Leader in KLH Manufacturing

Only producer WW of sustainable, scalable and fully-traceable GMP-grade KLH

Marine biotechnology pioneer with unique strengths:

Only-in-class aquaculture facility

Decades of experience across a range of disciplines

Industry firsts in aquaculture science

Advantageous location

IP covering core KLH business + new R&D

High barriers to entry

5-10 years and $20+ million investment ahead of any potential competitor

Fiscal strength

Cash, cash equivalents and short-term investments of $13.9 million (at Fiscal Year Ended 8/31/2014)

Supply Dynamics Favor Stellar Biotech

KLH molecule is large and complex; has not been synthesized

One marine source, one location

Commercial scale constraints

Giant Keyhole Limpet requires 5 years until fully mature

Protein-rich hemocyanin can be extracted 3X/year

1 gram GMP KLH has commercial value ~ $50,000

Stellar’s current production capacity is 1,000 gram GMP KLH – scalable to 4,000 gram GMP KLH

The Commercial Power of KLH Multiple High-Value Pathways

Revenue & Alliances L-T Supply Agreements Direct Sales Co-Development Research Collaborations Joint Ventures

Partners & Markets Major Biopharma Immunotherapy Immunotoxicology Immunodiagnostics Basic Research

Clinical Applications Cancers Immune Disorders Alzheimer’s Inflammatory Disease Immune Function Testing

Stellar KLH™ Carriers, Adjuvants, and Finished Products World-Leading Stellar KLH™ Platform

Stellar KLH™ Products

Stellar KLH™ Protein

Vaccine Carriers

Products for Immune Function Testing

Custom Formulations

New Supply Agreements

Araclon Biotech SL (Spain) – November 2014

Supply Stellar KLH™ for use in Araclon’s beta amyloid-targeting immunotherapy against Alzheimer’s disease

Biovest, Inc. – October 2014

Supply Stellar KLH™ for use in Biovest’s BiovaxID® immunotherapy to treat non-Hodgkin’s lymphoma

		Phase I/II	Phase II	Phase III	MAA Review	EMA Approval
BiovaxID®	N-H Lymphoma

Key Strategic Corporate Partner

Amaran Biotechnology (Taiwan)

Invested $5 million in Stellar’s 2013 financing

Evaluate and develop Stellar KLH™ as a potential carrier molecule for OBI Pharma’s OBI-822 immunotherapy

OBI-822 Active Immunotherapy breast cancer

KLH is key ingredient

		Preclinical	Phase I/II	Phase II	Phase III
OBI-822	Metastatic Breast Cancer  (Taiwan)
	Metastatic Breast Cancer  (U.S., So. Korea, India, Hong Kong)
	Ovarian  (Taiwan)

Long-Term Customer, Multiple Targets

Neovacs S.A. (Alternext Paris: ALNEV)

Kinoid immunotherapy pipeline

Stellar KLH™ used as carrier molecule

2 drugs in clinical development

		Preclinical	Phase I	Phase II	Phase III
TNF-Kinoid	Crohn’s disease
IFNa-Kinoid	Lupus

Future Milestones & Catalysts

New collaborations and supply contracts with biopharma partners

R&D in KLH-based immunotherapy

Aquaculture production capacity and expansion

Public company maturation

Prepare for major U.S. exchange

Corporate governance & controls

Regulatory advancements

USP monograph

Investigational New Drug (IND) application

Senior Executive Leadership

Frank Oakes

President & CEO

35 years experience; biotechnology and aquaculture. Aquaculture industry leader and KLH manufacturing expert. Formerly CEO of Abalone Farms, Inc.; leader through R&D, capitalization and commercialization to become first profitable and largest abalone producer in U.S.

Catherine Brisson, Ph.D.

Chief Operating Officer

20 years experience; biotech, pharma and medical device industries, including Sicor Pharmaceuticals (Teva Parenteral Products). Expertise in QA, QC, Regulatory and Manufacturing. Ph.D. Organic Chemistry.

Kathi Niffenegger

Chief Financial Officer

30 years experience; accounting and finance, range of industries including pharma. Outside CPA to Stellar since Company founding. Previously partner at Glenn Burdette, CFO at Martin Aviation, Peat Marwick, Mitchell (KPMG LLP).

Mark McPartland

VP, Corporate Development & Communications

16 years experience; business development, capital markets advisory, corporate communications. Previously Senior VP at MZ Group, VP and Partner at Alliance Advisors LLP, and Regional VP of Hayden Communications.

Key Facts & Selected Financials

Key Company Facts

Trading Symbols:

OTCQB: SBOTF

TSX-V: KLH

Headquarters: Port Hueneme, CA

Founded: 1999

Fiscal Year End: August 31

Independent Auditor:

Moss Adams LLP

Los Angeles, CA

Outside Legal Counsel:

Greenberg Traurig, LLP

McMillan LLP

Selected Financials

(All $ amounts in U.S.)

Updated 1/09/2015
Stock Price OTCQB $1.13

52 – Week Range $0.60-$2.36

Shares Outstanding 79.55M

Average Trade Volume (90 day) 158,865

Market Capitalization $89.9M

Debt * $0

Cash, Equivalents, Short Term Investments * $13.9M

* As of Fiscal Year End 8/31/2014

Shareholders Equity * $7.7M

Stellar Financial Filings:  http://ir.stellarbiotechnologies.com/all-sec-filings

Stellar Biotechnologies Summary

Industry-leading core competency in KLH

Versatile technology platform and products

KLH essential to immunotherapy, fastest-growing biopharma sector

Multiple, high-value commercial pathways

Progressive achievements and collaborations

Environmental champion

Fiscal strength = ability to execute

Powering and Improving Immunotherapy™

Frank R. Oakes

President & CEO

Office +1 (805) 488-2800

IR@stellarbiotech.com

Mark A. McPartland

V.P. Corporate Development & Communications

Office +1 (805) 488-2800 ext. 103

markmcp@stellarbiotech.com

OTCQB: SBOTF / TSX-V: KLH

www.StellarBiotech.com

www.KLHsite.org